Comprehensive Tumor Profiling

Caris molecular profiling utilizes a comprehensive approach to assess DNA, RNA and proteins to reveal a molecular blueprint to guide more precise and individualized treatment decisions.
dna-solid-lt-blue-fl-sky.svg

DNA

Whole Exome Sequencing (SNVs, Indels, Copy Number Alterations, Karyotyping & Viruses)

rna-solid-lt-blue-connect-sky.svg

RNA

Whole Transcriptome Sequencing (Gene Fusions and Variant Transcripts)

protein-solid-lt-sky-blue.svg

Protein

Immunohistochemistry (Tumor Relevant Protein Biomarkers)

Tumor Profiling Options

Print/Download

The information below details the biomarkers analyzed by technology for the tumor type submitted. Tests may vary if insufficient tumor samples are submitted. Certain assays and features may vary by location.

MI Profile Comprehensive Testing

MI Tumor Seek Hybrid™ + IHCs and Other Tests by Tumor Type: Tissue-based WES and WTS analysis, plus additional tumor-type relevant biomarker testing. Caris FOLFIRSTai™ reported for mCRC cases.

Next-Generation Sequencing Only

MI Tumor Seek Hybrid™: Tissue-based WES and WTS analysis. Caris FOLFIRSTai™ reported for mCRC cases.

Next-Generation Sequencing (all tumor types)

Whole Exome Sequencing
Alterations SNVs, Indels, CNAs, Karyotyping, Viruses
Genomic Signatures/Other gLOH, HRD, MSI, TMB, HLA Genotyping
Whole Transcriptome Sequencing
Alterations Gene Fusions and Variant Transcripts

AI-Powered Molecular Signatures

Caris GPSai™
Cancer type similarity assessment that is intended to help identify the tumor of origin by comparing the molecular characteristics of the patient's tumor against other tumors in the Caris database.
Caris FOLFIRSTai™
Chemotherapy response predictor that is intended to gauge a mCRC patient's likelihood of benefit from first-line FOLFOX+BV followed by FOLFIRI+BV, versus FOLFIRI+BV followed by FOLFOX+BV treatment.
Tumor Type:
Select tumor type to see specific tests to be performed

Tumor Type Immunohistochemistry (IHC) Other
Bladder Her2/Neu, MMR, PD-L1 (22c3)
Breast AR, ER, Her2/Neu, PD-L1 (22c3), PR, PTEN
Cancer of Unknown Primary – Female AR, ER, Her2/Neu, MMR, PD-L1 (SP142)
Cancer of Unknown Primary – Male AR, HER2/Neu, MMR, PD-L1 (SP142)
Cervical ER, Her2/Neu, MMR, PD-L1 (22c3), PR
Cholangiocarcinoma/ Hepatobiliary Her2/Neu, MMR, PD-L1 (SP142)
Colorectal and Small Intestinal Her2/Neu, MMR, PD-L1 (SP142), PTEN
Endometrial (all except uterine sarcoma) ER, Her2/Neu, MMR, PD-L1 (SP142), PR, PTEN
Esophageal Cancer Her2/Neu, MMR, PD-L1 (22c3)
Gastric/GEJ CLDN18, Her2/Neu, MMR, PD-L1 (22c3) EBER (Chromogenic in situ Hybridization)
GIST MMR, PD-L1 (SP142), PTEN
Glioma - MGMT Methylation (Pyrosequencing)
Head & Neck MMR, p16, PD-L1 (22c3) EBER, HPV (Chromogenic in situ Hybridization), HPV reflex to confirm p16 result
Kidney MMR, PD-L1 (SP142)
Melanoma MMR, PD-L1 (SP142)
Merkel Cell MMR, PD-L1 (SP142)
Neuroendocrine MMR, PD-L1 (SP142)
Non-Small Cell Lung ALK†, PD-L1 (22c3, 28-8, SP142, SP263), PTEN
Ovarian ER, Her2/Neu, FOLR1#, MMR, PD-L1 (22c3), PR
Pancreatic MMR, PD-L1 (SP142)
Prostate AR, MMR, PD-L1 (SP142)
Salivary Gland AR, Her2/Neu, MMR, PD-L1 (SP142)
Sarcoma MMR, PD-L1 (SP142)
Small Cell Lung PD-L1 (22c3)
Thyroid MMR, PD-L1 (SP142)
Uterine Sarcoma ER, MMR, PD-L1 (SP142), PR, PTEN
Vulvar Cancer (SCC) MMR, PD-L1 (22c3)
Other Tumors MMR, PD-L1 (SP142)

MMR = Mismatch Repair proteins: MLH1, MSH2, MSH6, PMS2.

†ALK IHC only performed for NSCLC adenocarcinoma.

#FOLR1 IHC, Her2/Neu IHC and HRD Status only performed for epithelial ovarian cancer.

Order Profiling

Place an order today for a comprehensive, personalized Caris profiling report.

Order

  • Caris applies the appropriate tumor-specific customizations standard with every order.
  • In certain instances, some biomarkers or genes ordered individually will not associate with commercially available cancer therapies or clinical trials.
  • For PD-L1 IHC testing, Dako antibodies 22c3, 28-8 and antibodies SP-142 and SP263 are used as appropriate.
  • For certain patients, HER2 testing is performed by Chromogenic in situ Hybridization, in addition to Next-Generation Sequencing.

Reflex Testing Menu

Comprehensive molecular profiling from Caris Life Sciences® assesses DNA, RNA, and proteins with multiple technologies including next-generation sequencing

Sufficient tumor content (>20% tumor nuclei) must be present to complete all analyses. If you have any questions, please contact Customer Support at (888) 979-8669.

Technical Information IHC CISH
Sample Requirements
(see requisition for full details)		 1 unstained slide at 4μm thickness from FFPE block, with evaluable tumor present, per IHC test 1 unstained slide at 4μm thickness from FFPE block, with at least 100 evaluable tumor cells present, per CISH test
Sensitivity/Specificity >95% >95%
Technical Information NGS (Whole Exome – DNA) NGS (Whole Transcriptome – RNA)
Sample Requirements ≥20% tumor nuclei. Accepted specimen types: FFPE block, unstained slides, core needle biopsy, fine needle aspirate, malignant fluid cell block, bone/bone metastasis. See Tumor Profiling Requisition for complete details.
Tumor Enrichment (when necessary) Microdissection to isolate and increase the number of cancer cells to improve test performance and increase the chance for successful testing from small tumor samples
Number of Genes 23,000+ genes 23,000+ genes
Average Depth of Coverage (DNA)
Average Read Count (RNA)		 1,500x for clinical genes 17 million reads
Positive Percent Agreement (PPA) >97% for base substitutions at ≥ 5% mutant allele frequency;
>97% for indels at ≥ 5% mutant allele frequency;
>95% for copy number alterations (amplifications ≥ 6 copies)		 >96%
Negative Percent Agreement (NPA) >99% >99%
Alterations SNVs, Indels, CNAs, Karyotyping, Viruses Gene Fusions and Variant Transcripts
Viruses HPV 16 & 18 (Head & Neck, Anal, Genital, CUP)
Genomic Signatures/Other Genomic Loss of Heterozygosity (gLOH)
Homologous Recombination Deficiency (HRD)
Microsatellite Instability (MSI)
Tumor Mutational Burden (TMB)
Human Leukocyte Antigen (HLA) Genotype
_______________________
Caris FOLFIRSTai™
Caris GPSai™

ABL ABL1 ACVR1 AIP AKT1 AKT2 AKT3 ALK AMER1 APC
AR ARAF ARHGAP26 ARHGAP35 ARID1A ARID2 AR-V7 ASXL1 ATM ATR
ATRX AXIN1 AXIN2 AXL B2M BAP1 BARD1 BCL2 BCL9 BCOR
BCR BLM BMPR1A BRAF BRCA1 BRCA2 BRD3 BRD4 BRIP1 BTK
CALR CARD11 CASP8 CBFB CCND1 CCND2 CCND3 CD79B CDC73 CDH1
CDK12 CDK4 CDK6 CDKN1B CDKN2A CHEK1 CHEK2 CIC CREBBP CSF1R
CTCF CTNNA1 CTNNB1 CXCR4 CYLD CYP17A1 DDR2 DICER1 DNMT3A EGFR
EGFR vIII EGLN1 ELF3 EP300 EPHA2 ERBB2 ERBB3 ERBB4 ERCC2 ERG
ESR1 ETV1 ETV4 ETV5 ETV6 EWSR1 EXO1 EZH2 FANCA FANCB
FANCC FANCD2 FANCE FANCF FANCG FANCI FANCL FANCM FAS FAT1
FBXW7 FGFR1 FGFR2 FGFR3 FGFR4 FGR FH FLCN FLT1 FLT3
FLT4 FOLR1 FOXA1 FOXL2 FUBP1 FYN GALNT12 GATA3 GLI2 GNA11
GNA13 GNAQ GNAS H3F3A H3F3B HDAC1 HIST1H3B HIST1H3C HNF1A HOXB13
HRAS IDH1 IDH2 INSR IRF4 JAK1 JAK2 JAK3 KDM5C KDM6A
KDR KEAP1 Ki-67 KIF1B KIT KLF4 KMT2A KMT2C KMT2D KRAS
LCK LYN LZTR1 MAML2 MAP2K1 MAP2K2 MAP2K4 MAP3K1 MAPK1 MAPK3
MAST1 MAST2 MAX MED12 MEF2B MEN1 MET MET Exon 14 Skipping MGA MITF
MLH1 MLH3 MPL MRE11 MSH2 MSH3 MSH6 MSMB MST1R MTOR
MUSK MUTYH MYB MYC MYCN MYD88 NBN NF1 NF2 NFE2L2
NFKBIA NOTCH1 NOTCH2 NPM1 NRAS NRG1 NSD1 NTHL1 NTRK1 NTRK2
NTRK3 NUMBL NUTM1 PALB2 PARP1 PBRM1 PDGFRA PDGFRB PHOX2B PIK3CA
PIK3CB PIK3R1 PIK3R2 PIM1 PKN1 PMS1 PMS2 POLD1 POLD2 POLD3
POLD4 POLE POLQ POT1 PPARG PPP2R1A PPP2R2A PRDM1 PRKACA PRKAR1A
PRKCA PRKCB PRKDC PTCH1 PTEN PTPN11 RABL3 RAC1 RAD50 RAD51B
RAD51C RAD51D RAD54L RAF1 RASA1 RB1 RELA RET RHOA RNF43
ROS1 RPA1 RPA2 RPA3 RPA4 RSPO2 RSPO3 RUNX1 SDHA SDHAF2
SDHB SDHC SDHD SETD2 SF3B1 SMAD2 SMAD4 SMARCA4 SMARCB1 SMARCE1
SMO SOCS1 SPEN SPOP SRC SSBP1 STAG2 STAT3 STK11 SUFU
SUZ12 TCF7L2 TERT TET2 TFE3 TFEB THADA TMEM127 TMPRSS2 TNFAIP3
TNFRSF14 TP53 TRAF7 TSC1 TSC2 U2AF1 VHL WRN WT1 XPO1
XRCC1 XRCC2 YES1

Tumor Profiling Options

Print/Download

The information below details the biomarkers analyzed by technology for the tumor type submitted. Tests may vary if insufficient tumor samples are submitted. Certain assays and features may vary by location.

MI Profile™ – Multi-platform, solid tumor biomarker analysis

The technology platforms used and biomarkers tested may vary based on the tumor type submitted. Technologies include: NGS (whole exome sequencing for DNA mutations, copy number alterations, insertions/deletions, genomic signatures: LOH, MSI, TMB; and whole transcriptome sequencing for RNA fusions and variant transcripts), pyro sequencing, IHC, in situ hybridization.

MI Tumor Seek™ – NGS analysis

Whole exome sequencing for DNA mutations, copy number alterations, insertions/deletions, genomic signatures LOH, MSI, and TMB, and whole transcriptome sequencing for RNA fusions and variant transcripts. Add Immuno-Oncology IHC biomarkers (included in MI Profile):

  • PD-L1
  • MMR (MLH1, MSH2, MSH6, PMS2)

Next-Generation Sequencing (all tumor types)

Whole Exome Sequencing
Alterations SNVs, Indels, CNAs
Genomic Signatures/Other gLOH, MSI, TMB
Whole Transcriptome Sequencing
Alterations Gene Fusions and Variant Transcripts
Tumor Type:
Select tumor type to see specific tests to be performed

Tumor Type Immunohistochemistry (IHC) Other
Bladder Her2/Neu, MMR, PD-L1 (22c3)
Breast AR, ER, Her2/Neu, PD-L1 (22c3), PR, PTEN Her2 (Chromogenic in situ Hybridization) reflex
Cancer of Unknown Primary – Female AR, ER, Her2/Neu, MMR, PD-L1 (SP142)
Cancer of Unknown Primary – Male AR, HER2/Neu, MMR, PD-L1 (SP142)
Cervical ER, Her2/Neu, MMR, PD-L1 (22c3), PR
Cholangiocarcinoma/ Hepatobiliary Her2/Neu, MMR, PD-L1 (SP142) Her2 (Chromogenic in situ Hybridization)
Colorectal and Small Intestinal Her2/Neu, MMR, PD-L1 (SP142), PTEN Her2 (Chromogenic in situ Hybridization) reflex
Endometrial ER, Her2/Neu, MMR, PD-L1 (SP142), PR, PTEN
Esophageal Cancer Her2/Neu, MMR, PD-L1 (22c3)
Gastric/GEJ CLDN18, Her2/Neu, MMR, PD-L1 (22c3) EBER
GIST MMR, PD-L1 (SP142), PTEN
Glioma - MGMT Methylation (Pyrosequencing)
Head & Neck MMR, p16, PD-L1 (22c3) EBER, HPV (Chromogenic in situ Hybridization), HPV reflex to confirm p16 result
Kidney MMR, PD-L1 (SP142)
Melanoma MMR, PD-L1 (SP142)
Merkel Cell MMR, PD-L1 (SP142)
Neuroendocrine MMR, PD-L1 (SP142)
Non-Small Cell Lung ALK†, PD-L1 (22c3, 28-8, SP142, SP263), PTEN
Ovarian ER, Her2/Neu, FOLR1#, MMR, PD-L1 (22c3), PR
Pancreatic MMR, PD-L1 (SP142)
Prostate AR, MMR, PD-L1 (SP142)
Salivary Gland AR, Her2/Neu, MMR, PD-L1 (SP142)
Sarcoma MMR, PD-L1 (SP142)
Small Cell Lung PD-L1 (22c3)
Thyroid MMR, PD-L1 (SP142)
Uterine Sarcoma ER, MMR, PD-L1 (SP142), PR, PTEN
Vulvar Cancer (SCC) MMR, PD-L1 (22c3)
Other Tumors MMR, PD-L1 (SP142)

MMR = Mismatch Repair proteins: MLH1, MSH2, MSH6, PMS2.

†ALK IHC only performed for NSCLC adenocarcinoma.

#FOLR1 IHC performed for epithelial ovarian cancer.

Order Profiling

Place an order today for a comprehensive, personalized Caris profiling report.

Order

  • Caris applies the appropriate tumor-specific customizations standard with every order.
  • In certain instances, some biomarkers or genes ordered individually will not associate with commercially available cancer therapies or clinical trials.
  • For PD-L1 IHC testing, Dako antibodies 22c3, 28-8 and antibodies SP-142 and SP263 are used as appropriate.
  • For certain patients, HER2 testing is performed by Chromogenic in situ Hybridization, in addition to Next-Generation Sequencing.

Reflex Testing Menu

Comprehensive molecular profiling from Caris Life Sciences® assesses DNA, RNA, and proteins with multiple technologies including next-generation sequencing

Sufficient tumor content (>20% tumor nuclei) must be present to complete all analyses. If you have any questions, please contact Customer Support at (888) 979-8669.

Technical Information IHC CISH
Sample Requirements
(see requisition for full details)		 1 unstained slide at 4μm thickness from FFPE block, with evaluable tumor present, per IHC test 1 unstained slide at 4μm thickness from FFPE block, with at least 100 evaluable tumor cells present, per CISH test
Sensitivity/Specificity >95% >95%
Technical Information NGS (Whole Exome – DNA) NGS (Whole Transcriptome – RNA)
Sample Requirements FFPE block or 10 unstained slides with a minimum of 20% malignant origin for DNA and 10% malignant origin for RNA. Needle biopsy is also acceptable (4-6 cores).
Tumor Enrichment (when necessary) Microdissection to isolate and increase the number of cancer cells to improve test performance and increase the chance for successful testing from small tumor samples
Number of Genes 22,000+ genes 22,000+ genes
Average Depth of Coverage (DNA)
Average Read Count (RNA)		 1,000x for clinical genes 60 million reads
Positive Percent Agreement (PPA) >95% for base substitutions at ≥ 5% mutant allele frequency;
>95% for indels at ≥ 5% mutant allele frequency;
>90% for copy number alterations (amplifications ≥ 6 copies)		 >97%
Negative Percent Agreement (NPA) >99% >99%
Genomic Signatures/Other Genomic Loss of Heterozygosity (gLOH)
Microsatellite Instability (MSI)
Tumor Mutational Burden (TMB)

ABL ABL1 ACVR1 AIP AKT1 AKT2 AKT3 ALK AMER1 APC
AR ARAF ARHGAP26 ARHGAP35 ARID1A ARID2 AR-V7 ASXL1 ATM ATR
ATRX AXIN1 AXIN2 AXL B2M BAP1 BARD1 BCL2 BCL9 BCOR
BCR BLM BMPR1A BRAF BRCA1 BRCA2 BRD3 BRD4 BRIP1 BTK
CALR CARD11 CASP8 CBFB CCND1 CCND2 CCND3 CD79B CDC73 CDH1
CDK12 CDK4 CDK6 CDKN1B CDKN2A CHEK1 CHEK2 CIC CREBBP CSF1R
CTCF CTNNA1 CTNNB1 CXCR4 CYLD CYP17A1 DDR2 DICER1 DNMT3A EGFR
EGFR vIII EGLN1 ELF3 EP300 EPHA2 ERBB2 ERBB3 ERBB4 ERCC2 ERG
ESR1 ETV1 ETV4 ETV5 ETV6 EWSR1 EXO1 EZH2 FANCA FANCB
FANCC FANCD2 FANCE FANCF FANCG FANCI FANCL FANCM FAS FAT1
FBXW7 FGFR1 FGFR2 FGFR3 FGFR4 FGR FH FLCN FLT1 FLT3
FLT4 FOLR1 FOXA1 FOXL2 FUBP1 FYN GALNT12 GATA3 GLI2 GNA11
GNA13 GNAQ GNAS H3F3A H3F3B HDAC1 HIST1H3B HIST1H3C HNF1A HOXB13
HRAS IDH1 IDH2 INSR IRF4 JAK1 JAK2 JAK3 KDM5C KDM6A
KDR KEAP1 Ki-67 KIF1B KIT KLF4 KMT2A KMT2C KMT2D KRAS
LCK LYN LZTR1 MAML2 MAP2K1 MAP2K2 MAP2K4 MAP3K1 MAPK1 MAPK3
MAST1 MAST2 MAX MED12 MEF2B MEN1 MET MET Exon 14 Skipping MGA MITF
MLH1 MLH3 MPL MRE11 MSH2 MSH3 MSH6 MSMB MST1R MTOR
MUSK MUTYH MYB MYC MYCN MYD88 NBN NF1 NF2 NFE2L2
NFKBIA NOTCH1 NOTCH2 NPM1 NRAS NRG1 NSD1 NTHL1 NTRK1 NTRK2
NTRK3 NUMBL NUTM1 PALB2 PARP1 PBRM1 PDGFRA PDGFRB PHOX2B PIK3CA
PIK3CB PIK3R1 PIK3R2 PIM1 PKN1 PMS1 PMS2 POLD1 POLD2 POLD3
POLD4 POLE POLQ POT1 PPARG PPP2R1A PPP2R2A PRDM1 PRKACA PRKAR1A
PRKCA PRKCB PRKDC PTCH1 PTEN PTPN11 RABL3 RAC1 RAD50 RAD51B
RAD51C RAD51D RAD54L RAF1 RASA1 RB1 RELA RET RHOA RNF43
ROS1 RPA1 RPA2 RPA3 RPA4 RSPO2 RSPO3 RUNX1 SDHA SDHAF2
SDHB SDHC SDHD SETD2 SF3B1 SMAD2 SMAD4 SMARCA4 SMARCB1 SMARCE1
SMO SOCS1 SPEN SPOP SRC SSBP1 STAG2 STAT3 STK11 SUFU
SUZ12 TCF7L2 TERT TET2 TFE3 TFEB THADA TMEM127 TMPRSS2 TNFAIP3
TNFRSF14 TP53 TRAF7 TSC1 TSC2 U2AF1 VHL WRN WT1 XPO1
XRCC1 XRCC2 YES1

Tumor Profiling Options

Print/Download

The information below details the biomarkers analyzed by technology for the tumor type submitted. Tests may vary if insufficient tumor samples are submitted. Certain assays and features may vary by location.

MI Tumor SeekTM

Next-Generation Sequencing analysis. Whole exome sequencing and whole transcriptome sequencing are performed.

AI-Powered Molecular Signatures

Caris GPSai™
Cancer type similarity assessment that is intended to help identify the tumor of origin by comparing the molecular characteristics of the patient's tumor against other tumors in the Caris database.
Caris FOLFIRSTai™
Chemotherapy response predictor that is intended to gauge a mCRC patient's likelihood of benefit from first-line FOLFOX+BV followed by FOLFIRI+BV, versus FOLFIRI+BV followed by FOLFOX+BV treatment.

Next-Generation Sequencing (all tumor types)

Whole Exome Sequencing
Alterations SNVs, Indels, CNAs, Karyotyping, Viruses
Genomic Signatures/Other gLOH, MSI, TMB, HLA Genotyping
Whole Transcriptome Sequencing
Alterations Gene Fusions and Variant Transcripts

Order Profiling

Place an order today for a comprehensive, personalized Caris profiling report.

Order

  • Caris applies the appropriate tumor-specific customizations standard with every order.
  • In certain instances, some biomarkers or genes ordered individually will not associate with commercially available cancer therapies or clinical trials.
  • For PD-L1 IHC testing, Dako antibodies 22c3, 28-8 and antibodies SP-142 and SP263 are used as appropriate.
  • For certain patients, HER2 testing is performed by Chromogenic in situ Hybridization, in addition to Next-Generation Sequencing.

Reflex Testing Menu

Comprehensive molecular profiling from Caris Life Sciences® assesses DNA, RNA, and proteins with multiple technologies including next-generation sequencing

Sufficient tumor content (>20% tumor nuclei) must be present to complete all analyses. If you have any questions, please contact International Customer Support at 00 41 21 533 53 00.

Technical Information NGS (Whole Exome – DNA) NGS (Whole Transcriptome – RNA)
Sample Requirements FFPE block or 10 unstained slides with a minimum of 20% malignant origin for DNA and 10% malignant origin for RNA. Needle biopsy is also acceptable (4-6 cores).
Tumor Enrichment (when necessary) Microdissection to isolate and increase the number of cancer cells to improve test performance and increase the chance for successful testing from small tumor samples
Number of Genes 22,000+ genes 22,000+ genes
Average Depth of Coverage (DNA)
Average Read Count (RNA)		 1,000x for 719+ genes; 400-500x for all other genes 60 million reads
Positive Percent Agreement (PPA) >95% for base substitutions at ≥ 5% mutant allele frequency;
>95% for indels at ≥ 5% mutant allele frequency;
>90% for copy number alterations (amplifications ≥ 6 copies)		 >97%
Negative Percent Agreement (NPA) >99% >99%
Genomic Signatures/Other Genomic Loss of Heterozygosity (gLOH)
Microsatellite Instability (MSI)
Tumor Mutational Burden (TMB)
Human Leukocyte Antigen (HLA) Genotype

ABL ABL1 ACVR1 AIP AKT1 AKT2 AKT3 ALK AMER1 APC
AR ARAF ARHGAP26 ARHGAP35 ARID1A ARID2 AR-V7 ASXL1 ATM ATR
ATRX AXIN1 AXIN2 AXL B2M BAP1 BARD1 BCL2 BCL9 BCOR
BCR BLM BMPR1A BRAF BRCA1 BRCA2 BRD3 BRD4 BRIP1 BTK
CALR CARD11 CASP8 CBFB CCND1 CCND2 CCND3 CD79B CDC73 CDH1
CDK12 CDK4 CDK6 CDKN1B CDKN2A CHEK1 CHEK2 CIC CREBBP CSF1R
CTCF CTNNA1 CTNNB1 CXCR4 CYLD CYP17A1 DDR2 DICER1 DNMT3A EGFR
EGFR vIII EGLN1 ELF3 EP300 EPHA2 ERBB2 ERBB3 ERBB4 ERCC2 ERG
ESR1 ETV1 ETV4 ETV5 ETV6 EWSR1 EXO1 EZH2 FANCA FANCB
FANCC FANCD2 FANCE FANCF FANCG FANCI FANCL FANCM FAS FAT1
FBXW7 FGFR1 FGFR2 FGFR3 FGFR4 FGR FH FLCN FLT1 FLT3
FLT4 FOLR1 FOXA1 FOXL2 FUBP1 FYN GALNT12 GATA3 GLI2 GNA11
GNA13 GNAQ GNAS H3F3A H3F3B HDAC1 HIST1H3B HIST1H3C HNF1A HOXB13
HRAS IDH1 IDH2 INSR IRF4 JAK1 JAK2 JAK3 KDM5C KDM6A
KDR KEAP1 Ki-67 KIF1B KIT KLF4 KMT2A KMT2C KMT2D KRAS
LCK LYN LZTR1 MAML2 MAP2K1 MAP2K2 MAP2K4 MAP3K1 MAPK1 MAPK3
MAST1 MAST2 MAX MED12 MEF2B MEN1 MET MET Exon 14 Skipping MGA MITF
MLH1 MLH3 MPL MRE11 MSH2 MSH3 MSH6 MSMB MST1R MTOR
MUSK MUTYH MYB MYC MYCN MYD88 NBN NF1 NF2 NFE2L2
NFKBIA NOTCH1 NOTCH2 NPM1 NRAS NRG1 NSD1 NTHL1 NTRK1 NTRK2
NTRK3 NUMBL NUTM1 PALB2 PARP1 PBRM1 PDGFRA PDGFRB PHOX2B PIK3CA
PIK3CB PIK3R1 PIK3R2 PIM1 PKN1 PMS1 PMS2 POLD1 POLD2 POLD3
POLD4 POLE POLQ POT1 PPARG PPP2R1A PPP2R2A PRDM1 PRKACA PRKAR1A
PRKCA PRKCB PRKDC PTCH1 PTEN PTPN11 RABL3 RAC1 RAD50 RAD51B
RAD51C RAD51D RAD54L RAF1 RASA1 RB1 RELA RET RHOA RNF43
ROS1 RPA1 RPA2 RPA3 RPA4 RSPO2 RSPO3 RUNX1 SDHA SDHAF2
SDHB SDHC SDHD SETD2 SF3B1 SMAD2 SMAD4 SMARCA4 SMARCB1 SMARCE1
SMO SOCS1 SPEN SPOP SRC SSBP1 STAG2 STAT3 STK11 SUFU
SUZ12 TCF7L2 TERT TET2 TFE3 TFEB THADA TMEM127 TMPRSS2 TNFAIP3
TNFRSF14 TP53 TRAF7 TSC1 TSC2 U2AF1 VHL WRN WT1 XPO1
XRCC1 XRCC2 YES1

Tumor Profiling Options

Print/Download

The information below details the biomarkers analyzed by technology for the tumor type submitted. Tests may vary if insufficient tumor samples are submitted. Certain assays and features may vary by location.

MI Profile Comprehensive Testing

MI Tumor Seek Hybrid™ + IHCs and Other Tests by Tumor Type: Tissue-based WES and WTS analysis, plus additional tumor-type relevant biomarker testing. Caris FOLFIRSTai™ reported for mCRC cases.

Next-Generation Sequencing Only

MI Tumor Seek Hybrid™: Tissue-based WES and WTS analysis. Caris FOLFIRSTai™ reported for mCRC cases.

Next-Generation Sequencing (all tumor types)

Whole Exome Sequencing
Alterations SNVs, Indels, CNAs, Karyotyping, Viruses
Genomic Signatures/Other gLOH, HRD, MSI, TMB, HLA Genotyping
Whole Transcriptome Sequencing
Alterations Gene Fusions and Variant Transcripts

AI-Powered Molecular Signatures

Caris GPSai™
Cancer type similarity assessment that is intended to help identify the tumor of origin by comparing the molecular characteristics of the patient's tumor against other tumors in the Caris database.
Caris FOLFIRSTai™
Chemotherapy response predictor that is intended to gauge a mCRC patient's likelihood of benefit from first-line FOLFOX+BV followed by FOLFIRI+BV, versus FOLFIRI+BV followed by FOLFOX+BV treatment.
Tumor Type:
Select tumor type to see specific tests to be performed

Tumor Type Immunohistochemistry (IHC) Other
Bladder Her2/Neu, MMR, PD-L1 (22c3)
Breast AR, ER, Her2/Neu, PD-L1 (22c3), PR, PTEN
Cancer of Unknown Primary – Female AR, ER, Her2/Neu, MMR, PD-L1 (SP142)
Cancer of Unknown Primary – Male AR, HER2/Neu, MMR, PD-L1 (SP142)
Cervical ER, Her2/Neu, MMR, PD-L1 (22c3), PR
Cholangiocarcinoma/ Hepatobiliary Her2/Neu, MMR, PD-L1 (SP142)
Colorectal and Small Intestinal Her2/Neu, MMR, PD-L1 (SP142), PTEN
Endometrial (all except uterine sarcoma) ER, MMR, PD-L1 (SP142), PR, PTEN
Esophageal Cancer Her2/Neu, MMR, PD-L1 (22c3)
Gastric/GEJ CLDN18, Her2/Neu, MMR, PD-L1 (22c3) EBER (Chromogenic in situ Hybridization)
GIST MMR, PD-L1 (SP142), PTEN
Glioma - MGMT Methylation (Pyrosequencing)
Head & Neck MMR, p16, PD-L1 (22c3) EBER, HPV (Chromogenic in situ Hybridization), HPV reflex to confirm p16 result
Kidney MMR, PD-L1 (SP142)
Melanoma MMR, PD-L1 (SP142)
Merkel Cell MMR, PD-L1 (SP142)
Neuroendocrine MMR, PD-L1 (SP142)
Non-Small Cell Lung ALK†, PD-L1 (22c3, 28-8, SP142, SP263), PTEN
Ovarian ER, Her2/Neu, FOLR1#, MMR, PD-L1 (22c3), PR
Pancreatic MMR, PD-L1 (SP142)
Prostate AR, MMR, PD-L1 (SP142)
Salivary Gland AR, Her2/Neu, MMR, PD-L1 (SP142)
Sarcoma MMR, PD-L1 (SP142)
Small Cell Lung PD-L1 (22c3)
Thyroid MMR, PD-L1 (SP142)
Uterine Sarcoma ER, MMR, PD-L1 (SP142), PR, PTEN
Vulvar Cancer (SCC) MMR, PD-L1 (22c3)
Other Tumors MMR, PD-L1 (SP142)

MMR = Mismatch Repair proteins: MLH1, MSH2, MSH6, PMS2.

†ALK IHC only performed for NSCLC adenocarcinoma.

#FOLR1 IHC, Her2/Neu IHC and HRD Status only performed for epithelial ovarian cancer.

Order Profiling

Place an order today for a comprehensive, personalized Caris profiling report.

Order

  • Caris applies the appropriate tumor-specific customizations standard with every order.
  • In certain instances, some biomarkers or genes ordered individually will not associate with commercially available cancer therapies or clinical trials.
  • For PD-L1 IHC testing, Dako antibodies 22c3, 28-8 and antibodies SP-142 and SP263 are used as appropriate.
  • For certain patients, HER2 testing is performed by Chromogenic in situ Hybridization, in addition to Next-Generation Sequencing.

Reflex Testing Menu

Comprehensive molecular profiling from Caris Life Sciences® assesses DNA, RNA, and proteins with multiple technologies including next-generation sequencing

Sufficient tumor content (>20% tumor nuclei) must be present to complete all analyses. If you have any questions, please contact International Customer Support at 00 41 21 533 53 00.

Technical Information IHC CISH
Sample Requirements
(see requisition for full details)		 1 unstained slide at 4μm thickness from FFPE block, with evaluable tumor present, per IHC test 1 unstained slide at 4μm thickness from FFPE block, with at least 100 evaluable tumor cells present, per CISH test
Sensitivity/Specificity >95% >95%
Technical Information NGS (Whole Exome – DNA) NGS (Whole Transcriptome – RNA)
Sample Requirements ≥20% tumor nuclei. Accepted specimen types: FFPE block, unstained slides, core needle biopsy, fine needle aspirate, malignant fluid cell block, bone/bone metastasis. See Tumor Profiling Requisition for complete details.
Tumor Enrichment (when necessary) Microdissection to isolate and increase the number of cancer cells to improve test performance and increase the chance for successful testing from small tumor samples
Number of Genes 23,000+ genes 23,000+ genes
Average Depth of Coverage (DNA)
Average Read Count (RNA)		 1,500x for clinical genes 17 million reads
Positive Percent Agreement (PPA) >97% for base substitutions at ≥ 5% mutant allele frequency;
>97% for indels at ≥ 5% mutant allele frequency;
>95% for copy number alterations (amplifications ≥ 6 copies)		 >96%
Negative Percent Agreement (NPA) >99% >99%
Alterations SNVs, Indels, CNAs, Karyotyping, Viruses Gene Fusions and Variant Transcripts
Viruses HPV 16 & 18 (Head & Neck, Anal, Genital, CUP)
Genomic Signatures/Other Genomic Loss of Heterozygosity (gLOH)
Homologous Recombination Deficiency (HRD)
Microsatellite Instability (MSI)
Tumor Mutational Burden (TMB)
Human Leukocyte Antigen (HLA) Genotype
_______________________
Caris FOLFIRSTai™
Caris GPSai™

ABL ABL1 ACVR1 AIP AKT1 AKT2 AKT3 ALK AMER1 APC
AR ARAF ARHGAP26 ARHGAP35 ARID1A ARID2 AR-V7 ASXL1 ATM ATR
ATRX AXIN1 AXIN2 AXL B2M BAP1 BARD1 BCL2 BCL9 BCOR
BCR BLM BMPR1A BRAF BRCA1 BRCA2 BRD3 BRD4 BRIP1 BTK
CALR CARD11 CASP8 CBFB CCND1 CCND2 CCND3 CD79B CDC73 CDH1
CDK12 CDK4 CDK6 CDKN1B CDKN2A CHEK1 CHEK2 CIC CREBBP CSF1R
CTCF CTNNA1 CTNNB1 CXCR4 CYLD CYP17A1 DDR2 DICER1 DNMT3A EGFR
EGFR vIII EGLN1 ELF3 EP300 EPHA2 ERBB2 ERBB3 ERBB4 ERCC2 ERG
ESR1 ETV1 ETV4 ETV5 ETV6 EWSR1 EXO1 EZH2 FANCA FANCB
FANCC FANCD2 FANCE FANCF FANCG FANCI FANCL FANCM FAS FAT1
FBXW7 FGFR1 FGFR2 FGFR3 FGFR4 FGR FH FLCN FLT1 FLT3
FLT4 FOLR1 FOXA1 FOXL2 FUBP1 FYN GALNT12 GATA3 GLI2 GNA11
GNA13 GNAQ GNAS H3F3A H3F3B HDAC1 HIST1H3B HIST1H3C HNF1A HOXB13
HRAS IDH1 IDH2 INSR IRF4 JAK1 JAK2 JAK3 KDM5C KDM6A
KDR KEAP1 Ki-67 KIF1B KIT KLF4 KMT2A KMT2C KMT2D KRAS
LCK LYN LZTR1 MAML2 MAP2K1 MAP2K2 MAP2K4 MAP3K1 MAPK1 MAPK3
MAST1 MAST2 MAX MED12 MEF2B MEN1 MET MET Exon 14 Skipping MGA MITF
MLH1 MLH3 MPL MRE11 MSH2 MSH3 MSH6 MSMB MST1R MTOR
MUSK MUTYH MYB MYC MYCN MYD88 NBN NF1 NF2 NFE2L2
NFKBIA NOTCH1 NOTCH2 NPM1 NRAS NRG1 NSD1 NTHL1 NTRK1 NTRK2
NTRK3 NUMBL NUTM1 PALB2 PARP1 PBRM1 PDGFRA PDGFRB PHOX2B PIK3CA
PIK3CB PIK3R1 PIK3R2 PIM1 PKN1 PMS1 PMS2 POLD1 POLD2 POLD3
POLD4 POLE POLQ POT1 PPARG PPP2R1A PPP2R2A PRDM1 PRKACA PRKAR1A
PRKCA PRKCB PRKDC PTCH1 PTEN PTPN11 RABL3 RAC1 RAD50 RAD51B
RAD51C RAD51D RAD54L RAF1 RASA1 RB1 RELA RET RHOA RNF43
ROS1 RPA1 RPA2 RPA3 RPA4 RSPO2 RSPO3 RUNX1 SDHA SDHAF2
SDHB SDHC SDHD SETD2 SF3B1 SMAD2 SMAD4 SMARCA4 SMARCB1 SMARCE1
SMO SOCS1 SPEN SPOP SRC SSBP1 STAG2 STAT3 STK11 SUFU
SUZ12 TCF7L2 TERT TET2 TFE3 TFEB THADA TMEM127 TMPRSS2 TNFAIP3
TNFRSF14 TP53 TRAF7 TSC1 TSC2 U2AF1 VHL WRN WT1 XPO1
XRCC1 XRCC2 YES1

Technical Specifications

Sufficient tumor content (>20% tumor nuclei) must be present to complete all analysis. If you have questions, please contact Customer Support at (888) 979-8669.

FFPE/SLIDE TISSUE

Tumor content: >20% tumor nuclei

Paraffin Block (Preferred)

Formalin fixed tissue block (including core-needle biopsies, fine-needle aspirates or malignant fluid)

Unstained Slides

25 slides

FRESH TISSUE

10% neutral buffered formalin

Four to six (4-6) biopsies with 18 gauge needle preferred

Six to ten (6-10) biopsies with 22 needle accepted

Caris Report Specs

Biomarker Analysis by Tumor Type

The information below details the biomarkers analyzed by technology for the tumor type submitted. Tests may vary if insufficient tumor samples are submitted.

Download Profile Menu for US and Intl PDF >

Download Profile Menu for New York State PDF >

Download Profile Menu for Europe PDF >

Looking for a Specific Gene?

Use our full gene search to verify that it is included in Caris profiling, or browse the list of genes most commonly associated with cancer.

Search Genes >

General Profile Menu (see above links for market specific menus)

All Biomarker Analysis includes:

Whole Exome Sequencing (WES)

DNA
Genomic
Signatures
Others
Point Mutations
Indels
Copy Number Alterations
HPV 16 and 18
MSI
TMB
LOH
HLA*
*Not available in New York state

Whole Transcriptome Sequencing (WTS)

RNA
Fusion Analysis
Variant Transcripts

Additional Testing:

Select tumor type to see specific tests to be performed.

Tumor Type:
No tumor selected
Tumor Type:
Select tumor type to see specific tests to be performed

Additional Information:

  • Caris applies the appropriate tumor-specific customizations standard with every order.
  • In certain instances, some biomarkers or genes ordered individually will not associate with commercially available cancer therapies or clinical trials.
  • For PD-L1 IHC testing, Dako antibodies 22c3, 28-8 and antibodies SP-142 and SP263 are used as appropriate.
  • For certain patients, HER2 testing is performed by Chromogenic in situ Hybridization, in addition to Next-Generation Sequencing.

REFLEX TESTING MENU >

Tumor Type:
Select tumor type to see specific tests to be performed
order now

Request Clinical/Scientific MSL Support

Please complete the form below to have a Caris Scientific Rep (Medical Science Liaison) contact you directly.

"*" indicates required fields

Name*
Preferred contact method*

Order a test

Place an order today for a comprehensive, personalized Caris profiling report.

Order